UTI Pharma & Healthcare Sector Fund bets on India’s growth story

The Indian pharmaceutical industry currently tops the chart amongst India’s science-based industries with wide ranging capabilities in the complex world of drug manufacture and technology.

The Indian pharmaceutical industry is now the third largest in the world in terms of volume and the Pharma market is expected to reach US$ 55 billion in 2020 from US$ 12.6 billion in 2009. The market has further potential to reach US$ 70 billion in an aggressive growth scenario.

UTI Pharma & Healthcare fund sized at around Rs.90 crore, is a fund that invests in stocks of companies engaged in manufacturing of pharmaceuticals, bulk drugs, formulations & OTC drugs, medical equipment & accessories etc.

The Fund has 14.25% in Sun Pharma, 12.9% in Dr. Reddy’s, 12.33% in Cipla, 9.28% in Lupin Ltd & 7.9% in Cadila Healthcare.

The fund managed by Lalit Nambiar, is suitable for a regular equity investor who has a higher risk apetite and can be used to complement the core portfolio holdings.